

Metrics Contract Services is a contract development and manufacturing organization (CDMO) offering a range of drug product development services from Phase I through Phase III CTM and commercial manufacturing for multiple dosage forms.

Metrics can provide product development that leverages proprietary pharmaceutical technologies in the areas of:

- **Customized Controlled Release Drug Delivery**
- **Bioavailability Enhancement**
- **Taste Masking (liquid and solid presentations)**

By collaborating with our partners, we use these technologies to develop and deliver novel prescription products that offer advantages over existing products and meet unmet medical needs.

When applied appropriately, these technologies can deliver therapeutic and convenience benefits to patients, including reduced dosing frequency, increased patient compliance, improved side effect profile and a more constant therapeutic effect.

### Controlled Release Delivery Systems

Metrics offers proprietary technologies for development of multiple forms of controlled release products:

- **Pulsed release** – pulses of drug concentrations over 12–24 hours following a single dose.
- **Sustained release** – steady levels of drug over 12–24 hours following a single dose.
- **Modified release** – immediate release of some drug and delayed release of the remainder.
- **Delayed release** – targets the drug to a specific site in the intestinal tract, particularly avoiding release in the stomach.

#### ***Benefits of customized controlled release may include:***

- Decreased dosing frequency
- Reduced peak-to-trough ratio of drug in systemic circulation
- Reduced rate of rise of drug concentration in blood
- Sustained and consistent blood levels within the therapeutic window
- Increased patient compliance
- Reduced side effects.



### Bioavailability Enhancement

SUBA™ is a novel drug delivery technology for enhancing the bioavailability of poorly water-soluble drugs. A solid dispersion is formed between the drug and specific pharmaceutically acceptable polymers. The dispersions, in powder form, are delivered to the body via hard gelatin capsules (but may also be incorporated within tablets). Once in the small intestine the drug/polymer combination changes form presenting the drug in such a way that it is more rapidly and consistently absorbed through the intestinal wall compared to standard crystalline forms of the drug.

***Potential benefits of using this technology include increased bioavailability, reduced intra/inter-patient variability and reduced side effects.***

### Taste Masking for Liquids and Tablets

Cleantaste™ technology allows polymer coating of individual drug crystals or granules (25–150µm diameter). Benefits can include; taste-masking, improved stability and in some cases sustained release characteristics.

The fine non-gritty texture of product produced by this technology lends itself to being used in orally dispersible tablet and liquid formulations, as well as encapsulated products.

***Cleantaste improves palatability and aids swallowing leading to improved patient compliance and ease of use.***